Pharmacokinetics of depot medroxyprogesterone acetate contraception

被引:0
|
作者
Mishell, DR [1 ]
机构
[1] UNIV SO CALIF,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90089
关键词
depo-medroxyprogesterone acetate; DMPA; contraception; injectable contraception; pharmacokinetics; pharmacodynamics; estradiol; ovulation; fertility; endometrium;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Depot medroxyprogesterone acetate (DMPA) is ail aqueous suspension of 17-acetoxy 6-methyl progestin administered by intramuscular injection for long-term contraception. This highly effective injectable formulation of medroxyprogesterone acetate (MPA) has a prolonged duration of action since the progestin is released slowly from the muscle. MPA is detected in the serum within 30 minutes after an injection of 150 mg. Serum concentrations vary between individual women but generally plateau at about 1.0 ng/mL for about three months, after which there is a gradual decline. In some women, MPA can be detected in the serum for as long as nine months after a single injection of 150 mg. The circulating MPA initially inhibits the midcycle leutinizing hormone (LH) peak, but LH and follicle stimulating hormone (FSH) levels remain in the range of those for the luteal phase of a pretreatment control cycle. Since ovulation is inhibited, serum progesterone levels remain low (< 0.4 ng/mL) for several months following an injection of DMPA. When MPA levels fall below 0.1 ng/mL, ovulation resumes. Thus, return to fertility is delayed for several months if a woman wishes to conceive after receiving one or move injections of DMPA. Following an injection of DMPA, serum estradiol levels initially are in the early to midfollicular phase range (mean approximately 50 pg/nL). Serum estradiol levels begin to rise about four months after a single injection when MPA levels fall below 0.5 ng/mL. For women who have used DMPA for several years, serum estradiol levels range between 10 and 92 pg/mL, with mean levels of about 40 pg/mL. Despite these low levels of estradiol, hot flushes are a rare event, and the vaginal epithelium remains moist and well rugated. Women using DMPA for several years do not observe a change in breast size. DMPA causes the endometrium to become atrophic, with small, straight endometrial glands and decidualized stroma. The cervical mucus remains thick and viscid. DMPA is a very effective form of contraception because of its multiple mechanisms of action and slow release into the circulation.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [41] THE CONTRACEPTIVE USE OF DEPOT MEDROXYPROGESTERONE ACETATE
    HICKEY, M
    FRASER, I
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1995, 38 (04): : 849 - 858
  • [42] Depot medroxyprogesterone acetate (DMPA) contraception in the United States: The first three years - Introduction to the symposium
    Kaunitz, AM
    Mishell, DR
    JOURNAL OF REPRODUCTIVE MEDICINE, 1996, 41 (05) : 379 - 380
  • [43] Zero pregnancies with new low dose depot medroxyprogesterone acetate subcutaneous injection for contraception.
    Darney, P
    Jain, J
    Jakimiuk, AJ
    FERTILITY AND STERILITY, 2004, 82 : S105 - S105
  • [44] Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception
    Clark, MK
    Sowers, M
    Levy, BT
    Tenhundfeld, P
    FERTILITY AND STERILITY, 2001, 75 (05) : 871 - 877
  • [45] High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
    Deborah Bartz
    Rie Maurer
    Jessica Kremen
    Jennifer M. Fortin
    Elizabeth Janiak
    Alisa B. Goldberg
    Contraception and Reproductive Medicine, 2 (1)
  • [46] Weight changes in users of depot medroxyprogesterone acetate intramuscular compared with women using nonhormonal contraception
    Rice, VM
    Weiss, R
    Kaunitz, AM
    OBSTETRICS AND GYNECOLOGY, 2005, 105 (04): : 58S - 59S
  • [47] MEDROXYPROGESTERONE ACETATE (MPA)1 FOR CONTRACEPTION
    SAJADI, HE
    BORAZJAN.G
    ARDEKANY, MS
    INTERNATIONAL JOURNAL OF FERTILITY, 1972, 17 (04) : 217 - 220
  • [48] MEDROXYPROGESTERONE ACETATE (MAP) PHARMACOKINETICS
    PANNUTI, F
    CAMAGGI, CM
    STROCCHI, E
    MARTONI, A
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1983, 19 (03): : R10 - R10
  • [49] Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion
    Steinauer, Jody E.
    Upadhyay, Ushma D.
    Sokoloff, Abby
    Harper, Cynthia C.
    Diedrich, Justin T.
    Drey, Eleanor A.
    CONTRACEPTION, 2015, 92 (06) : 553 - 559
  • [50] Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception
    Renee Heffron
    Urvi M. Parikh
    Kerri J. Penrose
    Nelly Mugo
    Deborah Donnell
    Connie Celum
    John W. Mellors
    Jared M. Baeten
    AIDS and Behavior, 2017, 21 : 2173 - 2179